- Home
- KALV vs BCSF Comparison
KALV vs BCSF Comparison
Compare KALV & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KALV | BCSF |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.7M | 818.0M |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KALV | BCSF |
|---|---|---|
| Price | $15.64 | $12.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $30.00 | $15.00 |
| AVG Volume (30 Days) | ★ 564.9K | 558.5K |
| Earning Date | 04-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 13.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.10 |
| Revenue | ★ $50,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $108.37 | N/A |
| P/E Ratio | ★ N/A | $12.06 |
| Revenue Growth | ★ 495.66 | N/A |
| 52 Week Low | $9.83 | $12.49 |
| 52 Week High | $19.00 | $19.21 |
Technical Indicators
Market Signals| Indicator | KALV | BCSF |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 38.88 |
| Support Level | $14.45 | $12.49 |
| Resistance Level | $16.33 | $14.53 |
| Average True Range (ATR) | 0.69 | 0.44 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 80.05 | 1.77 |
Price Performance
Historical ComparisonAbout KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.